Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors
Introduction
The epidermal growth factor receptor (EGFR) is over-expressed or dysregulated in a variety of solid tumours and plays a crucial role in their development, through involvement in increased cell proliferation and inhibition of apoptosis as well as enhancement of tumour vascularisation. Drug targeting of intracellular EGFR tyrosine kinase activity by gefitinib has resulted in a reduction in tumour growth and tumour cell death (Pao et al., 2004). Gefitinib (IRESSA®, AstraZeneca) is an anilinoquinazoline (4-quinazolinamine, N-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl) propoxy]) with a molecular weight of 446.9 Da. It is a lipophilic di-basic compound with a log DpH 7.4 of 3.9 and possesses two pKa-values of 5.28 and 7.17, and accordingly exhibits a pH-dependent solubility in gastrointestinal fluid. The solubility of gefitinib in aspirated human gastric fluid (pH 5.0) and intestinal fluid (pH 7.0) was 4.98 and 0.085 mg/ml, respectively (data on file, AstraZeneca). The oral bioavailability following an single dose of 250 mg gefitinib (IRESSA® tablet) as a free base in healthy male volunteers was 57% and manipulation of gastric pH to elevate it above five resulted in a 47% reduction of the relative bioavailability (data on file, AstraZeneca) (Swaisland et al., 2005). The maximum plasma concentration after a 250 mg dose gefitinib is typically observed after 5 h (Swaisland et al., 2005). As the in vivo intestinal permeability of gefitinib is predicted to be high based on data obtained in the Caco-2 model, we consider that the solubility and dissolution rate of gefitinib along the intestine might be the rate-limiting step in the absorption process. This is further supported by the observation that gefitinib undergoes rapid dissolution in acidic media but the solubility drops as pH increases to neutral intestinal pH (data on file, AstraZeneca). In summary, gefitinib is a Biopharmaceutical Classification System (BCS) class II compound, as the intestinal permeability is high and the solubility (and dissolution rate) is low along the intestine (Amidon et al., 1995).
Gefitinib is extensively distributed in the body and is mainly eliminated via metabolism and less than 0.5% (doses ranging from 1 to 75 mg) is excreted as unchanged gefitinib in urine (Swaisland et al., 2001). After a single oral dose of 50 mg radio-labelled gefitinib, 3.4 ± 1.0% was recovered in urine and 86.3 ± 6.6% (mean ± S.D.) was recovered in faeces of which only 12.1% was as parent drug in humans after sampling up to 240 h post-dose (Mckillop et al., 2004). Gefitinib and its metabolites are most likely eliminated by biliary and/or direct intestinal secretion.
The disposition kinetics of a 250 mg dose of gefitinib is characterized by a plasma half-life of about 39.7 h (range 26.9–83.2 h) in healthy volunteers (Swaisland et al., 2005). An analysis of the pharmacokinetic data from all healthy volunteer data generated during the clinical development of gefitinib showed that the majority of individuals orally dosed with gefitinib had post-absorptive plasma concentration time profiles that were biphasic with a terminal half-life in the order of 30 h. However, approximately 20% of the volunteer population had post-absorptive concentration–time profiles that were more monophasic in nature with an apparently shorter terminal half-life of about 10 h (data on file, AstraZeneca). Plausible explanations for the difference between these two groups with regards to plasma exposure might be differences in gastric emptying, drug dissolution and/or precipitation that affect existing absorption rate limitations and/or differences in metabolic capacity (i.e. clearance).
The Loc-I-Gut technique is a well established in vivo method for gastrointestinal intubation in humans and used for various biopharmaceutical and pharmacokinetic applications (Knutson et al., 1989, Petri et al., 2003, Lindahl et al., 1996, Tannergren et al., 2003, Sandstrom et al., 1998, Bonlokke et al., 1997, Bonlokke et al., 2001, Bonlokke et al., 1999, Lennernas et al., 1992). In the present study the Loc-I-Gut tube was introduced orally and once positioned in the jejunum a semi-open segment was created through inflation of the distal balloon, which offers well-defined conditions for in vivo investigations of dissolution and absorption of drugs (Fig. 1) (Bonlokke et al., 1997, Lennernas et al., 1992, Lindahl et al., 1997, Knutson et al., 1989). The present study was the first direct in vivo investigation in humans of the effect of precipitation and was aimed at studying changes of the drugs crystal structure on gastrointestinal absorption variables and the plasma exposure for a BCS class II drug such as gefitinib.
The main purpose of the study was to investigate whether the difference in plasma pharmacokinetic profiles between normal and altered healthy subjects might be explained by inter-individual variability in gastric emptying and/or precipitation/dissolution of gefitinib in the proximal small intestine by using a modification of an established in vivo intubation technique. The study also aimed to investigate the crystal form of the precipitated gefitinib in human jejunum by using Raman microscopy.
Section snippets
Subjects and study design
The study consisted of two separate consecutive study parts, study part I (SI) and study part II (SII). Both study parts were performed at the Clinical Research Department, University Hospital, Uppsala, Sweden and were separated by a minimum wash-out period of ten days. In SI, 100 healthy male subjects (aged 18–56 years and weighing 61–102 kg) were tested to determine and classify them on the basis of their pharmacokinetic (PK) profile of gefitinib following a single oral dose of 250 mg gefitinib
Pharmacokinetic assessment in study part I (SI)
All the subjects showed similar demographic (weight, height and age). Gefitinib was well tolerated by all subjects when given as a single dose of 250 mg as a tablet. The plasma concentration–time profiles and the pharmacokinetic variables of gefitinib after oral dosing in the two groups (in total 100 subjects) are shown in Fig. 2 and in Table 1. Each male subject was classified into one of the two groups based on their elimination half-life of gefitinib: (a) the normal group (N; t1/2 > 20 h) and,
Discussion
In the present in vivo absorption study we investigated whether the differences in plasma pharmacokinetic profiles of gefitinib between normal (t1/2 > 20 h) and altered (t1/2 < 20 h) healthy subjects might be explained by inter-individual variability of gastric dissolution, gastric emptying and/or subsequent precipitation of gefitinib in the proximal small intestine. In the screening part of the study, SI, we found that mean plasma exposure (AUC0−∞) was about 55% higher in the normal group compared
Acknowledgments
The authors would like to acknowledge the analytical support provided by Analytico Medinet BV, Bredan, NL.
These studies were funded by AstraZeneca and the authors have no conflict of interest relevant to the content of these studies.
References (27)
- et al.
Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans
Eur. J. Pharm. Sci.
(2001) - et al.
A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans
Eur. J. Pharm. Sci.
(1999) - et al.
Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers
Clin. Ther.
(2004) - et al.
Oral drug absorption studies: the best model for man is man!
Drug Discov. Today
(2001) - et al.
A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
J. Pharm. Biomed. Anal.
(2002) - et al.
The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids
Gastroenterology
(1990) - et al.
‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)
Semin. Cancer Biol.
(2004) - et al.
Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans
Gastroenterology
(1983) - et al.
Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5’-upstream regulatory region
Biochem. Biophys. Res. Commun.
(1999) - et al.
The role of gamma-scintigraphy in oral drug delivery
Adv. Drug Deliv. Rev.
(2001)
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability
Pharm. Res.
A new approach for direct in vivo dissolution studies of poorly soluble drugs
Pharm. Res.
A new technique for segmental jejunal perfusion in man
Am. J. Gastroenterol.
Cited by (58)
Pharmacokinetics, bioequivalence, and safety studies of gefitinib tablet formulations: A randomized, open-label, two-period, two-sequence crossover study in Chinese healthy volunteers
2023, Journal of Drug Delivery Science and TechnologyGefitinib-resveratrol Cocrystal with Optimized Performance in Dissolution and Stability
2022, Journal of Pharmaceutical SciencesThe Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study
2021, Journal of Pharmaceutical SciencesCitation Excerpt :This may be a result of the wide inter-subject variability in oral absorption pharmacokinetics,27,28,56–59 with a similar underprediction reported by Chen et al. (2018).12 This is likely to be a result of typical inter-subject variability in GI physiology or the result of variation in gastric emptying in addition to precipitation/dissolution of gefitinib in the GI tract.56,57,59 In addition, the post-prandial increase in stomach pH could alter the dissolution/solubility of gefitinib, however this would be balanced against the increased gefitinib solubility offered by the increased bile salts and volume expansion in the small-intestine, which together may contribute to this wide variability.8
p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer
2021, Journal of Controlled ReleaseUsing naso- and oro-intestinal catheters in physiological research for intestinal delivery and sampling in vivo: practical and technical aspects to be considered
2021, American Journal of Clinical NutritionAn enteric polymer mitigates the effects of gastric pH on oral absorption of poorly soluble weak acid drugs from supersaturable formulations: A case study with dantrolene
2020, European Journal of Pharmaceutics and Biopharmaceutics